Skip to main content
. Author manuscript; available in PMC: 2022 May 3.
Published in final edited form as: Cancer. 2020 Sep 5;126(22):4826–4837. doi: 10.1002/cncr.33159

Figure 3:

Figure 3:

The pathophysiology of exon 14 alterations. a) the MET structure. b) the impact of MET exon 14 alterations and development of exon 14 skipping. c) selected MET exon 14 alterations and the consequent lack of CBL binding, decreasing the MET polyubiniquitation and degradation

HGF: hepatocyte growth factor, CBL: Casitas B-lineage lymphoma, WT: wild-type, Δexon 14: exon 14 skipping.